T0	Outcomes 72 101	on early virological response
T1	Outcomes 266 308	increases early virological response (EVR)
T2	Outcomes 724 730	[SA]).
T3	Outcomes 731 734	HCV
T4	Outcomes 780 787	and 12.
T5	Outcomes 788 826	Ribavirin plasma trough concentrations
T6	Outcomes 975 1050	received nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens
T7	Outcomes 1066 1094	achieved an HCV RNA decrease
T8	Outcomes 1158 1175	P=0.017), but EVR
T9	Outcomes 1293 1319	of faster HCV RNA decrease
T10	Outcomes 1357 1369	younger age.
T11	Outcomes 1370 1378	RBV-C(4)
T12	Outcomes 1559 1580	a greater decrease in
T13	Outcomes 1632 1647	into higher EVR
T14	Outcomes 1726 1753	might improve HCV treatment